title: Is thrombotic microangiopathy associated with antitumoral activity?
authors.forename: Nicolas
authors.initials: N
authors.lastname: Chopin
authors.forename: Jérôme
authors.initials: J
authors.lastname: Alexandre
authors.forename: Charles
authors.initials: C
authors.lastname: Chapron
authors.forename: Laurence
authors.initials: L
authors.lastname: Moachon
authors.forename: François
authors.initials: F
authors.lastname: Goldwasser
mesh_terms: D058186:Acute Kidney Injury; D000959:Antihypertensive Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D005260:Female; D006463:Hemolytic-Uremic Syndrome / Q000139:chemically induced / Q000188:drug therapy*; D006801:Humans; D007668:Kidney / Q000098:blood supply; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000098:blood supply* / Q000188:drug therapy / Q000601:surgery; D000093542:Gemcitabine
chemical_list: D000959:Antihypertensive Agents; D003841:Deoxycytidine; D016190:Carboplatin; D000093542:Gemcitabine